Vancouver, BC / ACCESSWIRE / July 02, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that Brazos Minshew, Chief Executive Officer of Samuel J. Brant, LLC, former Chief Science Officer of TriVita, Inc., former Chief Executive Officer of Therapy Alternatives and Director of Marketing for Tiena Health, will assume the role of President of BioCell Labs, a wholly-owned subsidiary of Abattis Bioceuticals Corp. effective July 1, 2014. He will succeed Mike Withrow, who is resigning his role of President at BioCell to focus on leadership as Chief Executive Officer of Abattis Bioceuticals Corp. He will remain as Chairman of BioCell.
In announcing the appointment of Brazos Minshew, Mike Withrow, Chairman of the Board of Trustees, stated "We are all extremely pleased to bring a top caliber speaker, writer, teacher, researcher, and leader to BioCell Labs. Brazos Minshew has an outstanding record of achievement in product development with a $1 billion dollar product portfolio, in content development with over 200 published articles and 4 books, in writing Intellectual Properties such as International Patent and Trademark applications, and in presentations to healthcare professionals worldwide. He is committed to building on the Abattis reputation as the international leader in cannabis-based medications."
As CEO of Samuel J. Brant LLC, Brazos Minshew has organized volunteer educational efforts to address the literacy crisis of Native American youth. He also serves as the chairman of an International Medical Advisory Board that coordinates relief work in areas of desperate need, bringing together physicians from around the World: Japan, Chile, New York, Germany and the Canary Islands. He coordinates and administers a telemedicine program providing medical care in West Africa and other underserved areas worldwide.
As Chief Science Officer of TriVita, Inc., Brazos developed the products, messaging and IP around a catalogue of products reaching nearly $200 million (US) in sales annually. He became intimately familiar with Quality Control, raw ingredient sourcing, product formulations, manufacturing as well as the International legal requirement for more than a dozen Countries.
As CEO of Therapy Alternatives and Director of Marketing for Tiena Health, Brazos coordinated the clinical practice infrastructure of Family Physicians and Complementary Care providers, developing organizational disciplines that branded this as the Premier Practice in comprehensive care. His leadership resulted in growing annual revenue from $2.75 million (US) to over $10 million in only three years. For efforts in medical integration he was given the Pioneer in Medicine award in 2002.
Earlier in his career, Minshew taught at the Beijing University campus in Dallas, TX, served as a clinical researcher in Vancouver, BC with Occidental Institute Research Foundation and as Director of Clinical Research for Dallas College of Oriental Medicine. He conducted in-service trainings as a guest speaker at Albert Einstein School of Medicine in Queens, New York and Yale University's St. Raphael Hospital in New Haven, Connecticut.
Says Minshew, "As a speaker, writer and teacher I have travelled the world. I have communed with curanderos in Native Reservations and medicine men and women in the Amazon rainforest. I taught pharmacognosy seminars at the School of Pharmacy, Ankara, Turkey, provided Continuing Education to physicians at the Hospital Especialidades in Quetzaltenango, Guatemala, presented nutritional biochemistry at the University of Croatia, School of Pharmacy in Zagreb, Croatia and shared clinical research on cholesterol reduction at the African Conference of Cardiology in Port Louis, Mauritius. All of this to say that my career focus is to promote Traditional healing practices and revitalize the use of plant-based medicines to relieve human suffering."
Founded in 2010, BioCell Labs is the holder of numerous patented and proprietary products, a Health Canada MMPR license and a nutraceutical production facility. As President of BioCell Labs, Brazos Minshew is tasked with consolidating Intellectual Properties, refining production strategies and creating distribution logistics through aggressive project management.
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.
ON BEHALF OF THE BOARD
Michael Withrow, President & CEO
For further information, contact the Company's CEO, Michael Withrow at (778) 896-6536 or at [email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.